Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines

S Rico1 Centre d’Investigació de Medicaments, Institut de Recerca; Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;2 Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain

RM Antonijoan1 Centre d’Investigació de Medicaments, Institut de Recerca; Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;3 Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, Spain

MJ Barbanoj1 Centre d’Investigació de Medicaments, Institut de Recerca; Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;2 Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain;3 Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, SpainCorrespondence[email protected]

Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines

Figures & data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date